Literature DB >> 18272810

Vascular KCNQ potassium channels as novel targets for the control of mesenteric artery constriction by vasopressin, based on studies in single cells, pressurized arteries, and in vivo measurements of mesenteric vascular resistance.

Alexander R Mackie1, Lioubov I Brueggemann, Kyle K Henderson, Aaron J Shiels, Leanne L Cribbs, Karie E Scrogin, Kenneth L Byron.   

Abstract

Pressor effects of the vasoconstrictor hormone arginine vasopressin (AVP), observed when systemic AVP concentrations are less than 100 pM, are important for the physiological maintenance of blood pressure, and they are also the basis for therapeutic use of vasopressin to restore blood pressure in hypotensive patients. However, the mechanisms by which circulating AVP induces arterial constriction are unclear. We examined the novel hypothesis that KCNQ potassium channels mediate the physiological vasoconstrictor actions of AVP. Reverse transcriptase polymerase chain reaction revealed expression of KCNQ1, KCNQ4, and KCNQ5 in rat mesenteric artery smooth muscle cells (MASMCs). Whole-cell perforated patch recordings of voltage-sensitive K+ (Kv) currents in freshly isolated MASMCs revealed 1,3-dihydro-1-phenyl-3,3-bis(4-pyridinylmethyl)-2H-indol-2-one (linopirdine)- and 10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone (XE-991)-sensitive KCNQ currents that were electrophysiologically and pharmacologically distinct from other Kv currents. Suppression of KCNQ currents by AVP (100 pM) was associated with significant membrane depolarization, and it was abolished by the protein kinase C (PKC) inhibitor calphostin C (250 nM). The KCNQ channel blocker linopirdine (10 microM) inhibited KCNQ currents in MASMCs, and it induced constriction of isolated rat mesenteric arteries. The vasoconstrictor responses were not additive when combined with 30 pM AVP, and they were prevented by the L-type Ca2+ channel blocker verapamil. Ethyl-N-[2-amino-6-(4-fluorophenylmethylamino)pyridin-3-yl] carbamic acid (flupirtine) significantly enhanced KCNQ currents, and it reversed constrictor responses to 30 pM AVP. In vivo, i.v. administration of linopirdine induced a dose-dependent increase in mesenteric artery resistance and blood pressure, whereas flupirtine had the opposite effects. We conclude that physiological concentrations of AVP induce mesenteric artery constriction via PKC-dependent suppression of KCNQ currents and L-type Ca2+ channel activation in MASMCs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18272810      PMCID: PMC2597077          DOI: 10.1124/jpet.107.135764

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  47 in total

1.  Expression of voltage-dependent K(+) channel genes in mesenteric artery smooth muscle cells.

Authors:  C Xu; Y Lu; G Tang; R Wang
Journal:  Am J Physiol       Date:  1999-11

Review 2.  Pathways modulating neural KCNQ/M (Kv7) potassium channels.

Authors:  Patrick Delmas; David A Brown
Journal:  Nat Rev Neurosci       Date:  2005-11       Impact factor: 34.870

Review 3.  Molecular determinants of voltage-gated potassium currents in vascular smooth muscle.

Authors:  Robert H Cox
Journal:  Cell Biochem Biophys       Date:  2005       Impact factor: 2.194

4.  Possible vascular role of increased plasma arginine vasopressin in congestive heart failure.

Authors:  Tomohiro Nakamura; Hiroshi Funayama; Akio Yoshimura; Yoshio Tsuruya; Muneyasu Saito; Masanobu Kawakami; San-e Ishikawa
Journal:  Int J Cardiol       Date:  2006-01-13       Impact factor: 4.164

5.  TTX-sensitive voltage-gated Na+ channels are expressed in mesenteric artery smooth muscle cells.

Authors:  Roberto Berra-Romani; Mordecai P Blaustein; Donald R Matteson
Journal:  Am J Physiol Heart Circ Physiol       Date:  2005-07       Impact factor: 4.733

6.  Molecular and functional characterization of ERG, KCNQ, and KCNE subtypes in rat stomach smooth muscle.

Authors:  Susumu Ohya; Keiichi Asakura; Katsuhiko Muraki; Minoru Watanabe; Yuji Imaizumi
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2002-02       Impact factor: 4.052

Review 7.  A potassium channel, the M-channel, as a therapeutic target.

Authors:  Toral S Surti; Lily Y Jan
Journal:  Curr Opin Investig Drugs       Date:  2005-07

Review 8.  Physiology of vasopressin relevant to management of septic shock.

Authors:  C L Holmes; B M Patel; J A Russell; K R Walley
Journal:  Chest       Date:  2001-09       Impact factor: 9.410

9.  Protein kinase C shifts the voltage dependence of KCNQ/M channels expressed in Xenopus oocytes.

Authors:  Koichi Nakajo; Yoshihiro Kubo
Journal:  J Physiol       Date:  2005-09-22       Impact factor: 5.182

10.  Electrophysiological and functional effects of the KCNQ channel blocker XE991 on murine portal vein smooth muscle cells.

Authors:  Shuk Yin M Yeung; Iain A Greenwood
Journal:  Br J Pharmacol       Date:  2005-10       Impact factor: 8.739

View more
  74 in total

1.  Kv7 potassium channels in airway smooth muscle cells: signal transduction intermediates and pharmacological targets for bronchodilator therapy.

Authors:  Lioubov I Brueggemann; Priyanka P Kakad; Robert B Love; Julian Solway; Maria L Dowell; Leanne L Cribbs; Kenneth L Byron
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-09-30       Impact factor: 5.464

2.  Expression and function of the K+ channel KCNQ genes in human arteries.

Authors:  Fu Liang Ng; Alison J Davis; Thomas A Jepps; Maksym I Harhun; Shuk Yin Yeung; Andrew Wan; Marcus Reddy; David Melville; Antonio Nardi; Teck K Khong; Iain A Greenwood
Journal:  Br J Pharmacol       Date:  2011-01       Impact factor: 8.739

3.  Vascular KCNQ channels in humans: the sub-threshold brake that regulates vascular tone?

Authors:  Bharath K Mani; Kenneth L Byron
Journal:  Br J Pharmacol       Date:  2011-01       Impact factor: 8.739

4.  Diclofenac distinguishes among homomeric and heteromeric potassium channels composed of KCNQ4 and KCNQ5 subunits.

Authors:  Lioubov I Brueggemann; Alexander R Mackie; Jody L Martin; Leanne L Cribbs; Kenneth L Byron
Journal:  Mol Pharmacol       Date:  2010-09-28       Impact factor: 4.436

5.  Molecular and functional characterization of Kv7 K+ channel in murine gastrointestinal smooth muscles.

Authors:  Thomas A Jepps; Iain A Greenwood; James D Moffatt; Kenton M Sanders; Susumu Ohya
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-04-23       Impact factor: 4.052

6.  Effects of the Kv7 voltage-activated potassium channel inhibitor linopirdine in rat models of haemorrhagic shock.

Authors:  Sean P Nassoiy; Favin S Babu; Heather M LaPorte; Kenneth L Byron; Matthias Majetschak
Journal:  Clin Exp Pharmacol Physiol       Date:  2018-04-27       Impact factor: 2.557

7.  De novo expression of Kv6.3 contributes to changes in vascular smooth muscle cell excitability in a hypertensive mice strain.

Authors:  Alejandro Moreno-Domínguez; Pilar Cidad; Eduardo Miguel-Velado; José R López-López; M Teresa Pérez-García
Journal:  J Physiol       Date:  2008-12-15       Impact factor: 5.182

Review 8.  Flupirtine, a re-discovered drug, revisited.

Authors:  Istvan Szelenyi
Journal:  Inflamm Res       Date:  2013-01-16       Impact factor: 4.575

9.  Cardiovascular responses to retigabine in conscious rats--under normotensive and hypertensive conditions.

Authors:  L V Fretwell; J Woolard
Journal:  Br J Pharmacol       Date:  2013-07       Impact factor: 8.739

10.  Differential effects of selective cyclooxygenase-2 inhibitors on vascular smooth muscle ion channels may account for differences in cardiovascular risk profiles.

Authors:  Lioubov I Brueggemann; Alexander R Mackie; Bharath K Mani; Leanne L Cribbs; Kenneth L Byron
Journal:  Mol Pharmacol       Date:  2009-07-15       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.